Effect of N-Acetylcysteine in hemodialysis patients
Phase 2
- Conditions
- Condition 1: Hemodialysis patients. Condition 2: Hemodialysis patients. Condition 3: Hemodialysis patients.Renal failure
- Registration Number
- IRCT2014031216969N1
- Lead Sponsor
- Vice Chancellor for Development, Research and Technology of Ahvaz Jondishapour University of Medical
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
1) all of the chronic hemodialysis patients due to end stage renal disease more than 18 years old and at least three months has been past from starting of hemodialysis. Exclusion criteria: 1) Every acute disease leads to hospitalization from one month before trial. 2) Allergy to N-acetylcysteine. 3) Hepatic cirrhosis 4) Using Vitamin E or C or every known antioxidant from two weeks before intervention. 5) congestive heart failure or ejection fraction less than 35%. 6) Non using of N-acetylcysteine or placebo more than 20% of total drug.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum Malondialdehyde. Timepoint: Before intervention and 6 weeks after intervention. Method of measurement: With malondialdehyde kit spectrophotometry method in mmol/lit.
- Secondary Outcome Measures
Name Time Method Itching. Timepoint: Before intervention and 6 weeks after intervention. Method of measurement: Visual.